FDA-Approved Indications for Loratadine-Phenylephrine Combinations
Loratadine (an antihistamine) combined with phenylephrine (a decongestant) is approved for temporary relief of symptoms from upper respiratory allergies, including sneezing, runny nose, itchy/watery eyes, itching of nose or throat, and nasal congestion.[1] These products, like Claritin-D 12-Hour (loratadine 5 mg/phenylephrine 120 mg), target seasonal allergic rhinitis with congestion.[2]
No patents explicitly limit use to "specific medical conditions" beyond these indications; patents cover the formulation, method of use, or composition for treating allergic rhinitis and sinus congestion, not narrower diseases.[3]
Patented Formulations and Their Claims
Key patents for loratadine-phenylephrine combos (e.g., US Patent 8,163,798 and related) claim extended-release bilayer tablets for treating allergic conditions with nasal congestion, specifying doses like 5 mg loratadine and 120 mg phenylephrine for 12-hour relief.[4] DrugPatentWatch lists these for products like Alavert Allergy & Sinus D-12, protecting use in allergic rhinitis but not unique diseases.[3]
When Do Key Patents Expire?
Major patents on loratadine-phenylephrine formulations expired by 2020-2022, with some method-of-use extensions challenged via ANDA Paragraph IV filings.[3] No active exclusivity blocks generics for standard allergy indications as of 2024.[3][5]
Off-Label or Unapproved Uses
No evidence supports patented use for non-allergy conditions like hypertension or asthma; phenylephrine's vasoconstriction risks contraindicate such applications.[1] Patents do not cover these, and FDA warns against unapproved uses.[2]
Generic Availability and Competitors
Generics match approved indications (allergic rhinitis with congestion) at lower cost, from manufacturers like Perrigo and Teva. Competitors include pseudoephedrine-based options like Claritin-D 24-Hour, restricted due to meth precursor rules.[3][6]
Sources:
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021151s033lbl.pdf
[2] DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=someid
[3] DrugPatentWatch.com
[4] USPTO: https://patents.google.com/patent/US8163798
[5] FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[6] IQVIA Market Data